TNXP Tonix Pharmaceuticals Holding C

4.05
0  -1%
Previous Close 4.08
Open 4.00
Price To book 0.63
Market Cap 30.32M
Shares 7,486,000
Volume 106,708
Short Ratio 3.68
Av. Daily Volume 1,539,200

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initiation of first of two Phase 3 trials announced March 28, 2017 in military-related PTSD 1Q 2017. Interim analysis due 1H 2018 with top-line data due 2H 2018.
TNX-102 SL
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
TNX-201
Episodic tension-type headache
Phase 3 data released September 6, 2016. Primary endpoint not met. Program discontinued
TNX-102 SL
Fibromyalgia

Latest News

  1. TNXP: Potential for Only One Phase 3 Trial Needed for TNX-102 SL in PTSD
  2. Tonix reports 4Q loss
  3. Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
  4. Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
  5. Windtree Therapeutics and Tonix Pharmaceuticals on the Rise after FDA Clinical Trial News
  6. Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
  7. Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock
  8. Tonix Pipeline Review Closer to the Commercialization of a New PTSD Treatment
  9. Is This The Start of a Turnaround for DryShips and Tonix, or will Management Burn Investors Again
  10. Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
  11. Tonix Pharmaceuticals and Athersys Advance as FDA Clinical Trials Move Forward
  12. Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock
  13. Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
  14. Tuesday’s Top Biopharma Movers
  15. Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference
  16. Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
  17. Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
  18. Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference
  19. Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL
  20. TNXP: Developing New Smallpox Vaccine